The DOI matches its Crossref record; 220 of the 220 references it cites were found in a registry or an index.
Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment
Open accessAbstract
Cancer stem cells (CSCs), also known as tumor-initiating cells (TICs), are suggested to be responsible for drug resistance and cancer relapse due in part to their ability to self-renew themselves and differentiate into heterogeneous lineages of cancer cells. Thus, it is important to understand the characteristics and mechanisms by which CSCs display resistance to therapeutic agents. In this review, we highlight the key features and mechanisms that regulate CSC function in drug resistance as well as recent breakthroughs of therapeutic approaches for targeting CSCs. This promises new insights of CSCs in drug resistance and provides better therapeutic rationales to accompany novel anticancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–220 of 220
Yang, D., Ding, X., Luo, J., Shan, Y.-X., Wang, R., Lin, S.-J., Li, G., Huang, C., Zhu, J., Chen, Y., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.448142 · Cited by 52
Self-citationBMI1 induces an invasive signature in melanoma that promotes metastasis and chemoresistancePreprint
Ferretti, R., Bhutkar, A. J., McNamara, M. C., & Lees, J. A. (2015) · Genes & Development · doi:10.1101/gad.267757.115 · Cited by 52
López‐Lázaro, M. (2015) · Oncoscience · doi:10.18632/oncoscience.159 · Cited by 51
The E2F1-miRNA Cancer Progression Network
Knoll, S., Emmrich, S., & Pützer, B. M. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-5590-1_8 · Cited by 50
Ferrari, F., Bellone, S., Black, J., Schwab, C. L., Lopez, S., Cocco, E., Bonazzoli, E., Predolini, F., Menderes, G., Litkouhi, B., et al. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0241-7 · Cited by 44
Tetraspanins: Spanning from solid tumors to hematologic malignancies
Yang, Y., Sari, I. N., Zia, M. F., Lee, S. R., Song, S. J., & Kwon, H. Y. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.02.006 · Cited by 44
Self-citationTherapeutic strategies for targeting cancer stem cells
Kim, K. G., Siegler, E. L., Siriwon, N., & Wang, P. (2016) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2016.26 · Cited by 43
Self-citationMalek, R. A., Wang, H., Taparra, K., & Tran, P. T. (2017) · Cells Tissues Organs · doi:10.1159/000447238 · Cited by 41
EMP2 is a novel therapeutic target for endometrial cancer stem cells
Kiyohara, M., Dillard, C. M., Tsui, J. L., Kim, S. R., Lu, J., Sachdev, D., Goodglick, L., Tong, M., Torous, V. F., Aryasomayajula, C., et al. (2017) · Oncogene · doi:10.1038/onc.2017.142 · Cited by 39
Enhanced Chemosensitivity by Targeting Nanog in Head and Neck Squamous Cell Carcinomas
Huang, C.-E., Yu, C.-C., Hu, F., Chou, M. Y., & Tsai, L.-L. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150914935 · Cited by 34
Hes3 regulates cell number in cultures from glioblastoma multiforme with stem cell characteristics
Park, D. M., Jung, J., Masjkur, J. R., Makrogkikas, S., Ebermann, D., Saha, S., Rogliano, R., Paolillo, N., Pacioni, S., McKay, R. D. G., et al. (2013) · Scientific Reports · doi:10.1038/srep01095 · Cited by 34
STAT5 Is Crucial to Maintain Leukemic Stem Cells in Acute Myelogenous Leukemias Induced by MOZ-TIF2
Tam, W. F., Hähnel, P. S., Schüler, A., Lee, B. H., Okabe, R. O., Zhu, N., Pante, S. V., Raffel, G. D., Mercher, T., Wernig, G., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0255 · Cited by 34
Pine, S. R., Marshall, B., & Varticovski, L. (2008) · Disease Markers · doi:10.1155/2008/396281 · Cited by 33
Dependence of Castration‐Resistant Prostate Cancer (CRPC) Stem Cells on CRPC‐Associated Fibroblasts
Adisetiyo, H., Liang, M., Liao, C., Jeong, J. H., Cohen, M. B., Roy‐Burman, P., & Frenkel, B. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24546 · Cited by 31
Retinoic acid, CYP26, and drug resistance in the stem cell niche
Alonso, S., Jones, R. J., & Ghiaur, G. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.07.004 · Cited by 31
Overcoming Chemoresistance in Cancer Stem Cells with the Help of microRNAs in Colorectal Cancer
Fesler, A. T., Guo, S., Liu, H., Wu, N., & Ju, J. (2017) · Epigenomics · doi:10.2217/epi-2017-0041 · Cited by 30
Discovery and Exploitation of Novel Targets by Approved Drugs
Dirix, L. Y. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.7118 · Cited by 23
Immune Targeting of Tumor Epithelial–Mesenchymal Transition via Brachyury-Based Vaccines
Palena, C., & Hamilton, D. H. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.001 · Cited by 17
The Role of Cancer Stem Cells in Tumor Radioresistance
Kurth, I., Peitzsch, C., Baumann, M. A., & Dubrovska, A. (2014) · Wiley eBooks · doi:10.1002/9781118356203.ch35 · Cited by 10
(2003) · PubMed
Cited by
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
Stem cell programs in cancer initiation, progression, and therapy resistance
Huang, T., Song, X., Xu, D., Tiek, D., Goenka, A., Wu, B., Sastry, N., Hu, B., & Cheng, S.-Y. (2020) · Theranostics · doi:10.7150/thno.41648 · Cited by 524
Chemotherapy: a double-edged sword in cancer treatment
Behranvand, N., Nasri, F., Zolfaghari Emameh, R., Khani, P., Hosseini, A., Garssen, J., & Falak, R. (2022) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-021-03013-3 · Cited by 397
Gut microbiome and its role in colorectal cancer
Rebersek, M. (2021) · BMC Cancer · doi:10.1186/s12885-021-09054-2 · Cited by 355
Drug resistance in cancer: mechanisms and tackling strategies
Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00138-7 · Cited by 282
Metadata
- Authors
- Phi, L. T. H., Sari, I. N., Yang, Y.-G., Lee, S.-H., Jun, N., Kim, K. S., Lee, Y. K., & Kwon, H. Y.
- Venue
- Stem Cells International
- Publisher
- Wiley
- Published
- 2018
- Volume
- 2018
- Pages
- 1-16
- ISSN
- 1687-966X (ISSN-L)
- 1687-9678
- OpenAlex
- W2791923388
- Cited by
- 994
- References
- 220
- FWCI
- 28.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.